Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7596676,bioavailability,"The geometric mean bioavailability (range) was 3.0% (1.2-9.5%) in a proprietary dehydrated vegetable product, 3.0% (1.1-21.2%) in Weetabix whole-wheat breakfast cereal, 3.1% (1.2-15.4%) in wholemeal bread, and 4.3% (1.7-10.3%) in baked beans.",The bioavailability of iron in different weaning foods and the enhancing effect of a fruit drink containing ascorbic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596676/),%,3.0,421,DB00126,Vitamin C
,7596676,bioavailability,"The geometric mean bioavailability (range) was 3.0% (1.2-9.5%) in a proprietary dehydrated vegetable product, 3.0% (1.1-21.2%) in Weetabix whole-wheat breakfast cereal, 3.1% (1.2-15.4%) in wholemeal bread, and 4.3% (1.7-10.3%) in baked beans.",The bioavailability of iron in different weaning foods and the enhancing effect of a fruit drink containing ascorbic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596676/),%,3.0,422,DB00126,Vitamin C
,7596676,bioavailability,"The geometric mean bioavailability (range) was 3.0% (1.2-9.5%) in a proprietary dehydrated vegetable product, 3.0% (1.1-21.2%) in Weetabix whole-wheat breakfast cereal, 3.1% (1.2-15.4%) in wholemeal bread, and 4.3% (1.7-10.3%) in baked beans.",The bioavailability of iron in different weaning foods and the enhancing effect of a fruit drink containing ascorbic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596676/),%,3.1,423,DB00126,Vitamin C
,7596676,bioavailability,"The geometric mean bioavailability (range) was 3.0% (1.2-9.5%) in a proprietary dehydrated vegetable product, 3.0% (1.1-21.2%) in Weetabix whole-wheat breakfast cereal, 3.1% (1.2-15.4%) in wholemeal bread, and 4.3% (1.7-10.3%) in baked beans.",The bioavailability of iron in different weaning foods and the enhancing effect of a fruit drink containing ascorbic acid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596676/),%,4.3,424,DB00126,Vitamin C
,1473790,Urinary excretion,"Urinary excretion of benzanthrone in control and ascorbic acid-treated animals during 96 hr was 27.9 and 30.5%, respectively, with peak elimination at 48 hr.",Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,27.9,3101,DB00126,Vitamin C
,1473790,Urinary excretion,"Urinary excretion of benzanthrone in control and ascorbic acid-treated animals during 96 hr was 27.9 and 30.5%, respectively, with peak elimination at 48 hr.",Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,30.5,3102,DB00126,Vitamin C
,1473790,Faecal elimination,"Faecal elimination in control and supplemented animals during 96 hr was 24.5 and 38.8%, respectively, with a peak at 48 hr.",Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,24.5,3103,DB00126,Vitamin C
,1473790,Faecal elimination,"Faecal elimination in control and supplemented animals during 96 hr was 24.5 and 38.8%, respectively, with a peak at 48 hr.",Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,38.8,3104,DB00126,Vitamin C
,1473790,organ retention,The organ retention of radiolabelled benzanthrone at the end of 96 hr was of the order of 39% in control animals (gastro-intestinal tract 16%; liver 22%; testis 1.2%); ascorbic acid supplementation reduced benzanthrone retention to 19.5% (gastro-intestinal tract 12.7%; liver 6.8%).,Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,39,3105,DB00126,Vitamin C
,1473790,organ retention,The organ retention of radiolabelled benzanthrone at the end of 96 hr was of the order of 39% in control animals (gastro-intestinal tract 16%; liver 22%; testis 1.2%); ascorbic acid supplementation reduced benzanthrone retention to 19.5% (gastro-intestinal tract 12.7%; liver 6.8%).,Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,16,3106,DB00126,Vitamin C
,1473790,organ retention,The organ retention of radiolabelled benzanthrone at the end of 96 hr was of the order of 39% in control animals (gastro-intestinal tract 16%; liver 22%; testis 1.2%); ascorbic acid supplementation reduced benzanthrone retention to 19.5% (gastro-intestinal tract 12.7%; liver 6.8%).,Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,22,3107,DB00126,Vitamin C
,1473790,organ retention,The organ retention of radiolabelled benzanthrone at the end of 96 hr was of the order of 39% in control animals (gastro-intestinal tract 16%; liver 22%; testis 1.2%); ascorbic acid supplementation reduced benzanthrone retention to 19.5% (gastro-intestinal tract 12.7%; liver 6.8%).,Effect of extraneous supplementation of ascorbic acid on the bio-disposition of benzanthrone in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473790/),%,1,3108,DB00126,Vitamin C
< or =,15613930,AUC,"However, significant increases in AUC and Cmax, and a significant reduction in Tmax by adding AsA were observed in 25 patients with baseline AUC < or =2500 ng.hour/mL.",The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15613930/),[h·ng] / [ml],2500,8056,DB00126,Vitamin C
,26960680,di,"The model optimized fast dissolving film prepared from the dispersion was physically and chemically stable, demonstrated short disintegration time (8.5 s), fast dissolution (97% in 10 min) and optimum tensile strength (4.9 N/cm2).",In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),s,8.5,9529,DB00126,Vitamin C
,26960680,tensile strength,"The model optimized fast dissolving film prepared from the dispersion was physically and chemically stable, demonstrated short disintegration time (8.5 s), fast dissolution (97% in 10 min) and optimum tensile strength (4.9 N/cm2).",In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),[n] / [cm2],4.9,9530,DB00126,Vitamin C
,26960680,bioavailability,The results of in vivo data indicated high bioavailability (144 ng h/mL) and maximum plasma concentration (14.2 ng/mL) compared with the marketed references.,In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),[h·ng] / [ml],144,9531,DB00126,Vitamin C
,26960680,maximum plasma concentration,The results of in vivo data indicated high bioavailability (144 ng h/mL) and maximum plasma concentration (14.2 ng/mL) compared with the marketed references.,In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26960680/),[ng] / [ml],14.2,9532,DB00126,Vitamin C
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],200,9559,DB00126,Vitamin C
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],10,9560,DB00126,Vitamin C
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],25,9561,DB00126,Vitamin C
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],2.5,9562,DB00126,Vitamin C
,12235445,inhibition constant [K(i)],"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μg] / [ml],35.9,15936,DB00126,Vitamin C
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],87.0,15937,DB00126,Vitamin C
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],124.0,15938,DB00126,Vitamin C
,12235445,K(i),Ascorbyl palmitate was more potent (K(i) = 12.3 +/- 0.5 micromol/L).,Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],12.3,15939,DB00126,Vitamin C
,3108183,half-life,"Adrenalectomized rats excreted significantly less radioactivity, resulting in a significantly longer estimated half-life of AA (173 +/- 7 h) than the sham-adrenalectomized controls (141 +/- 7 h).",The effect of bilateral adrenalectomy on metabolism and tissue distribution of ascorbic acid in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108183/),h,173,18243,DB00126,Vitamin C
,3108183,half-life,"Adrenalectomized rats excreted significantly less radioactivity, resulting in a significantly longer estimated half-life of AA (173 +/- 7 h) than the sham-adrenalectomized controls (141 +/- 7 h).",The effect of bilateral adrenalectomy on metabolism and tissue distribution of ascorbic acid in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108183/),h,141,18244,DB00126,Vitamin C
,23529727,relative bioavailability,"Of the three tablet formulations, fast-release GSK1322322 provided pharmacokinetic profiles similar to those of the powder-in-bottle reference formulation (~93% relative bioavailability) and was selected for progression in part 2.","Effect of H2 blockade and food on single-dose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529727/),%,93,23361,DB00126,Vitamin C
,23529727,T(max),"Coadministration of GSK1322322 with an H2 blocker resulted in a slight delay in absorption (T(max) ~0.75 h later) and 58 and 38% decreases in the C(max) and AUC0-∞ values, respectively, compared to GSK1322322 alone.","Effect of H2 blockade and food on single-dose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529727/),h,0.75,23362,DB00126,Vitamin C
,1840323,half lives,"The half lives of the alpha, beta and gamma phases were 1.3, 8.1 and 27 min, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,1.3,24789,DB00126,Vitamin C
,1840323,half lives,"The half lives of the alpha, beta and gamma phases were 1.3, 8.1 and 27 min, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,8.1,24790,DB00126,Vitamin C
,1840323,half lives,"The half lives of the alpha, beta and gamma phases were 1.3, 8.1 and 27 min, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,27,24791,DB00126,Vitamin C
,1840323,mean residence time (MRT),"The mean residence time (MRT) and total clearance were 14.5 min and 78 ml/min/kg, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,14.5,24792,DB00126,Vitamin C
,1840323,total clearance,"The mean residence time (MRT) and total clearance were 14.5 min and 78 ml/min/kg, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),[ml] / [kg·min],78,24793,DB00126,Vitamin C
,1840323,Cmax,"When 3 mg/kg of E4101 were administered orally under fasting, E4101 in plasma reached the peak (Cmax: 22.4 ng/ml) 45 min after administration.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),[ng] / [ml],22.4,24794,DB00126,Vitamin C
,1840323,bioavailability,The bioavailability was 3.6%.,"Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),%,3.6,24795,DB00126,Vitamin C
,1840323,duration of effective plasma concentration,"When 10 mg/kg of E4101 in combination with 25 mg/kg of ascorbic acid as a sustained-release dosage form using oily somisolid matrix orally administered to non-fasted beagles, the duration of effective plasma concentration (2 ng/ml plasma in i.d. administration) was 8.4 +/- 1.0 hr (mean +/- SE, n-4).","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),h,2,24796,DB00126,Vitamin C
,1840323,duration of effective plasma concentration,"When 10 mg/kg of E4101 in combination with 25 mg/kg of ascorbic acid as a sustained-release dosage form using oily somisolid matrix orally administered to non-fasted beagles, the duration of effective plasma concentration (2 ng/ml plasma in i.d. administration) was 8.4 +/- 1.0 hr (mean +/- SE, n-4).","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),h,8.4,24797,DB00126,Vitamin C
,1840323,Cmax,The Cmax was 16.2 +/- 2.5 ng/ml.,"Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),[ng] / [ml],16.2,24798,DB00126,Vitamin C
,22589159,extraction recoveries,The extraction recoveries were from 74.0 to 95.8%.,Simultaneous determination of six isoflavonoids in rat plasma after administration of total flavonoid from Gegen by ultra-HPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22589159/),%,74.0 to 95.8,24828,DB00126,Vitamin C
,23670640,Half-life,"Half-life and clearance values were similar for all patients of all cohorts (2.0 ± 0.6 h, 21 ± 5 dL/h m², respectively).","Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23670640/),h,2.0,28800,DB00126,Vitamin C
,23670640,clearance,"Half-life and clearance values were similar for all patients of all cohorts (2.0 ± 0.6 h, 21 ± 5 dL/h m², respectively).","Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23670640/),[dl] / [h·m²],21,28801,DB00126,Vitamin C
,23670640,C(max),"C(max) and AUC values increased proportionately with dose between 0 and 70 g/m², but appeared to reach maximal values at 70 g/m² (49 mM and 220 h mM, respectively).","Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23670640/),mM,49,28802,DB00126,Vitamin C
,23670640,AUC,"C(max) and AUC values increased proportionately with dose between 0 and 70 g/m², but appeared to reach maximal values at 70 g/m² (49 mM and 220 h mM, respectively).","Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23670640/),mM,49,28803,DB00126,Vitamin C
,23670640,AUC,"C(max) and AUC values increased proportionately with dose between 0 and 70 g/m², but appeared to reach maximal values at 70 g/m² (49 mM and 220 h mM, respectively).","Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23670640/),h·mM,220,28804,DB00126,Vitamin C
,6714208,Vd(ss),The apparent volume of distribution (average value for Vd(ss) = 0.6 litre/kg) was approximately equivalent to the volume of total body water.,Pharmacokinetics of ascorbic acid in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714208/),[l] / [kg],0.6,29851,DB00126,Vitamin C
,6714208,terminal half-life,The terminal half-life of the biexponential serum level-time curve (t1/2 beta) varied between 5 and 17 h.,Pharmacokinetics of ascorbic acid in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714208/),h,5 and 17,29852,DB00126,Vitamin C
,6714208,bioavailability,"Following subcutaneous and im injection, the average bioavailability of ascorbic acid amounted to 82 and 61 per cent, respectively.",Pharmacokinetics of ascorbic acid in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714208/),%,82,29853,DB00126,Vitamin C
,6714208,bioavailability,"Following subcutaneous and im injection, the average bioavailability of ascorbic acid amounted to 82 and 61 per cent, respectively.",Pharmacokinetics of ascorbic acid in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714208/),%,61,29854,DB00126,Vitamin C
,2834531,clearances,"The clearances in the rat, estimated after the low and high doses (15.4 +/- 2.0 and 15.3 +/- 1.4 mL/min.kg, respectively), were about twofold higher than those observed in two beagles (7.4 and 7.1 mL/min.kg for Dog #1 and 6.3 and 6.0 mL/min.kg for Dog #2).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),[ml] / [kg·min],15.4,33267,DB00126,Vitamin C
,2834531,clearances,"The clearances in the rat, estimated after the low and high doses (15.4 +/- 2.0 and 15.3 +/- 1.4 mL/min.kg, respectively), were about twofold higher than those observed in two beagles (7.4 and 7.1 mL/min.kg for Dog #1 and 6.3 and 6.0 mL/min.kg for Dog #2).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),[ml] / [kg·min],15.3,33268,DB00126,Vitamin C
,2834531,clearances,"The clearances in the rat, estimated after the low and high doses (15.4 +/- 2.0 and 15.3 +/- 1.4 mL/min.kg, respectively), were about twofold higher than those observed in two beagles (7.4 and 7.1 mL/min.kg for Dog #1 and 6.3 and 6.0 mL/min.kg for Dog #2).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),[ml] / [kg·min],7.4,33269,DB00126,Vitamin C
,2834531,clearances,"The clearances in the rat, estimated after the low and high doses (15.4 +/- 2.0 and 15.3 +/- 1.4 mL/min.kg, respectively), were about twofold higher than those observed in two beagles (7.4 and 7.1 mL/min.kg for Dog #1 and 6.3 and 6.0 mL/min.kg for Dog #2).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),[ml] / [kg·min],7.1,33270,DB00126,Vitamin C
,2834531,clearances,"The clearances in the rat, estimated after the low and high doses (15.4 +/- 2.0 and 15.3 +/- 1.4 mL/min.kg, respectively), were about twofold higher than those observed in two beagles (7.4 and 7.1 mL/min.kg for Dog #1 and 6.3 and 6.0 mL/min.kg for Dog #2).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),[ml] / [kg·min],6.3,33271,DB00126,Vitamin C
,2834531,clearances,"The clearances in the rat, estimated after the low and high doses (15.4 +/- 2.0 and 15.3 +/- 1.4 mL/min.kg, respectively), were about twofold higher than those observed in two beagles (7.4 and 7.1 mL/min.kg for Dog #1 and 6.3 and 6.0 mL/min.kg for Dog #2).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),[ml] / [kg·min],6.0,33272,DB00126,Vitamin C
,2834531,urinary recoveries,"In both animal species, the urinary recoveries of the dose as unchanged TAP and its hydroxylamine were essentially complete for the 24-h urine collections (92 to 98% and 83 to 95% for the rats and the dogs, respectively).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),%,92 to 98,33273,DB00126,Vitamin C
,2834531,urinary recoveries,"In both animal species, the urinary recoveries of the dose as unchanged TAP and its hydroxylamine were essentially complete for the 24-h urine collections (92 to 98% and 83 to 95% for the rats and the dogs, respectively).",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),%,83 to 95,33274,DB00126,Vitamin C
,2834531,renal clearance,"Renal excretion of unchanged TAP was the predominant route of elimination, as renal clearance was estimated to be between 47 and 89% of total clearance in the dogs.",Pharmacokinetics in the rat and the dog of a nonionic nitroxide contrast agent for magnetic resonance imaging. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834531/),%,47 and 89,33275,DB00126,Vitamin C
,17622258,area under the curve (AUC),"When [6S]-5-CH(3)H(4)PteGlu was concurrently administered with 289.4 or 973.8 mg L-AA, the total serum folate response, calculated as the area under the curve (AUC), was significantly improved (46.5+/-4.0 and 53.0+/-4.0 vs 34.3+/-3.8 h nmol/l, P<0.05).",L-ascorbic acid improves the serum folate response to an oral dose of [6S]-5-methyltetrahydrofolic acid in healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622258/),[h·nM] / [l],46.5,33678,DB00126,Vitamin C
,17622258,area under the curve (AUC),"When [6S]-5-CH(3)H(4)PteGlu was concurrently administered with 289.4 or 973.8 mg L-AA, the total serum folate response, calculated as the area under the curve (AUC), was significantly improved (46.5+/-4.0 and 53.0+/-4.0 vs 34.3+/-3.8 h nmol/l, P<0.05).",L-ascorbic acid improves the serum folate response to an oral dose of [6S]-5-methyltetrahydrofolic acid in healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622258/),[h·nM] / [l],53.0,33679,DB00126,Vitamin C
,17622258,area under the curve (AUC),"When [6S]-5-CH(3)H(4)PteGlu was concurrently administered with 289.4 or 973.8 mg L-AA, the total serum folate response, calculated as the area under the curve (AUC), was significantly improved (46.5+/-4.0 and 53.0+/-4.0 vs 34.3+/-3.8 h nmol/l, P<0.05).",L-ascorbic acid improves the serum folate response to an oral dose of [6S]-5-methyltetrahydrofolic acid in healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622258/),[h·nM] / [l],34.3,33680,DB00126,Vitamin C
,19134103,T(max-,Abomasal emptying rate was significantly (P<0.05) faster in group E (T(max-model)=182+/-69 min; mean+/-SD) than in group C cows (T(max-model)=237+/-64 min).,Effect of preoperative erythromycin or dexamethasone/vitamin C on postoperative abomasal emptying rate in dairy cows undergoing surgical correction of abomasal volvulus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19134103/),min,182,37277,DB00126,Vitamin C
,19134103,T(max-model),Abomasal emptying rate was significantly (P<0.05) faster in group E (T(max-model)=182+/-69 min; mean+/-SD) than in group C cows (T(max-model)=237+/-64 min).,Effect of preoperative erythromycin or dexamethasone/vitamin C on postoperative abomasal emptying rate in dairy cows undergoing surgical correction of abomasal volvulus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19134103/),min,237,37278,DB00126,Vitamin C
,19134103,T(max-model),Abomasal emptying rate was similar in group D (T(max-model)=196+/-47 min) and group C.,Effect of preoperative erythromycin or dexamethasone/vitamin C on postoperative abomasal emptying rate in dairy cows undergoing surgical correction of abomasal volvulus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19134103/),min,196,37279,DB00126,Vitamin C
,32036253,relative bioavailability,"In addition, the relative bioavailability of M10-H to M10-Na in Wistar rats was 60 ± 19%, calculated by the ratio of area under concentration (AUC) of M10-H to M10-Na after intragastrical administration of a single dose (100 mg·kg-1 for M10-H and M10-Na, respectively) in Wistar rats.",Preclinical pharmacokinetics of M10 after intragastrical administration of M10-H and M10-Na in Wistar rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32036253/),%,60,38917,DB00126,Vitamin C
less,2924379,t 1/2,Oxantrazole was relatively unstable in fresh mouse and dog plasma and particularly unstable in fresh human plasma (t 1/2 less than 5 min at 37 degrees C).,"Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924379/),min,5,42400,DB00126,Vitamin C
,2924379,elimination-phase half-life,"Following rapid i.v. administration of oxantrazole to mice, plasma elimination was best described by a two-compartment open model with an elimination-phase half-life, total body clearance, and steady-state volume of distribution of 330 min, 458 ml/min per m2, and 87.9 l/m2, respectively.","Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924379/),min,330,42401,DB00126,Vitamin C
,2924379,total body clearance,"Following rapid i.v. administration of oxantrazole to mice, plasma elimination was best described by a two-compartment open model with an elimination-phase half-life, total body clearance, and steady-state volume of distribution of 330 min, 458 ml/min per m2, and 87.9 l/m2, respectively.","Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924379/),[ml] / [m2·min],458,42402,DB00126,Vitamin C
,2924379,steady-state volume of distribution,"Following rapid i.v. administration of oxantrazole to mice, plasma elimination was best described by a two-compartment open model with an elimination-phase half-life, total body clearance, and steady-state volume of distribution of 330 min, 458 ml/min per m2, and 87.9 l/m2, respectively.","Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924379/),[l] / [m2],87.9,42403,DB00126,Vitamin C
,2924379,c x t,The c x t value calculated following i.v. administration of 90 mg/m2 oxantrazole to mice was 177 micrograms-min/ml.,"Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924379/),[μgrams-min] / [ml],177,42404,DB00126,Vitamin C
,1359893,detection limit,"The method has a detection limit of 2 ng/ml, it proved to have good accuracy and precision, and was linear in the range of 2 to 400 ng/ml.",Determination of pipamperone in human plasma by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359893/),[ng] / [ml],2,44476,DB00126,Vitamin C
,15767232,C max,"Mean steady-state indinavir C max was significantly reduced (20%) after 7 days of vitamin C administration (10.3 +/- 1.5 vs 8.2 +/- 2.9 microg/ml, p=0.04).",Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767232/),[μg] / [ml],10.3,46917,DB00126,Vitamin C
,15767232,C max,"Mean steady-state indinavir C max was significantly reduced (20%) after 7 days of vitamin C administration (10.3 +/- 1.5 vs 8.2 +/- 2.9 microg/ml, p=0.04).",Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767232/),[μg] / [ml],8.2,46918,DB00126,Vitamin C
,15767232,AUC 0-8,"The corresponding mean AUC 0-8 was also significantly decreased (14%; 26.4 +/- 7.2 vs 22.7 +/- 8.1 microg*hr/ml, p=0.05).",Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767232/),[h·μg] / [ml],26.4,46919,DB00126,Vitamin C
,15767232,AUC 0-8,"The corresponding mean AUC 0-8 was also significantly decreased (14%; 26.4 +/- 7.2 vs 22.7 +/- 8.1 microg*hr/ml, p=0.05).",Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767232/),[h·μg] / [ml],22.7,46920,DB00126,Vitamin C
,15767232,C min,"Although not statistically significant, the mean indinavir C min was 32% lower in the presence of vitamin C (0.27 +/- 0.17 C vs 0.18 +/- 0.08 microg/ml, p=0.09).",Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767232/),c,0.27,46921,DB00126,Vitamin C
,15767232,C min,"Although not statistically significant, the mean indinavir C min was 32% lower in the presence of vitamin C (0.27 +/- 0.17 C vs 0.18 +/- 0.08 microg/ml, p=0.09).",Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767232/),[μg] / [ml],0.18,46922,DB00126,Vitamin C
,978441,apparent biological half-life,The apparent biological half-life of acetaminophen increased from 2.3 +/- 0.2 (mean +/- SD) to 3.1 +/- 0.5 hr.,Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/978441/),h,2.3,48404,DB00126,Vitamin C
,978441,apparent biological half-life,The apparent biological half-life of acetaminophen increased from 2.3 +/- 0.2 (mean +/- SD) to 3.1 +/- 0.5 hr.,Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/978441/),h,3.1,48405,DB00126,Vitamin C
less,12064344,half-life,Catechins from the extract were excreted into urine with a half-life of less than 2 h in accordance with the short-term effects on plasma antioxidant capacity.,Green tea extract only affects markers of oxidative status postprandially: lasting antioxidant effect of flavonoid-free diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064344/),h,2,52123,DB00126,Vitamin C
,9095337,bioavailability,"Zilascorb(2H) in tablet formulation had a bioavailability of 32%, was quickly absorbed and slowly eliminated.","Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9095337/),%,32,56726,DB00126,Vitamin C
,22477200,AUC,The results showed moderate oral bioavailability of prodrugs (AUC = 53-94 h · μg/mL) in rats compared with parent Nap (AUC = 155 h · μg/mL) at equimolar doses.,Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477200/),[h·μg] / [ml],53-94,60385,DB00126,Vitamin C
,22477200,AUC,The results showed moderate oral bioavailability of prodrugs (AUC = 53-94 h · μg/mL) in rats compared with parent Nap (AUC = 155 h · μg/mL) at equimolar doses.,Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22477200/),[h·μg] / [ml],155,60386,DB00126,Vitamin C
,7429760,maximum amount,The linearisation of the relationship between ingested dose and the excreted amount in urine yielded a maximum amount of 1160 mg ascorbic acid which can be absorbed in 24 h under the conditions of the experiment.,"Absorption of large, single, oral intakes of ascorbic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7429760/),mg,1160,63549,DB00126,Vitamin C
,33246284,half-life time,The results showed that clevidipine was rapidly eliminated with a short half-life time of 0.244 ± 0.125 h and a maximum concentration of 25.2 ± 7.09 ng/mL.,Development and validation of samples stabilization strategy and LC-MS/MS method for simultaneous determination of clevidipine and its primary metabolite in human plasma: Application to clinical pharmacokinetic study in Chinese healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246284/),h,0.244,67949,DB00126,Vitamin C
,33246284,maximum concentration,The results showed that clevidipine was rapidly eliminated with a short half-life time of 0.244 ± 0.125 h and a maximum concentration of 25.2 ± 7.09 ng/mL.,Development and validation of samples stabilization strategy and LC-MS/MS method for simultaneous determination of clevidipine and its primary metabolite in human plasma: Application to clinical pharmacokinetic study in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246284/),[ng] / [ml],25.2,67950,DB00126,Vitamin C
,33246284,half-life time,H152/81 was detectable in the plasma samples up to 48.5 h with a half-life time of 10.7 ± 2.30 h and a maximum plasma concentration of 301 ± 38.1 ng/mL.,Development and validation of samples stabilization strategy and LC-MS/MS method for simultaneous determination of clevidipine and its primary metabolite in human plasma: Application to clinical pharmacokinetic study in Chinese healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246284/),h,10.7,67951,DB00126,Vitamin C
,33246284,maximum plasma concentration,H152/81 was detectable in the plasma samples up to 48.5 h with a half-life time of 10.7 ± 2.30 h and a maximum plasma concentration of 301 ± 38.1 ng/mL.,Development and validation of samples stabilization strategy and LC-MS/MS method for simultaneous determination of clevidipine and its primary metabolite in human plasma: Application to clinical pharmacokinetic study in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246284/),[ng] / [ml],301,67952,DB00126,Vitamin C
,7019414,sensitivity,The sensitivity of the assay was 150 pmoles/ml.,High-performance liquid chromatographic analysis of captopril in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019414/),[pmoles] / [ml],150,72100,DB00126,Vitamin C
,7019414,terminal half-life,"Thereafter, the plasma levels declined rapidly, and the terminal half-life was approximately 40 min.",High-performance liquid chromatographic analysis of captopril in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019414/),min,40,72101,DB00126,Vitamin C
,22127588,total body clearance,"Ascorbic acid (200 mg/kg) altered colistin pharmacokinetics, as the total body clearance decreased from 3.78 ± 0.36 mL/min/kg (colistin group) to 2.46 ± 0.57 mL/min/kg (P = 0.0024).",Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22127588/),[ml] / [kg·min],3.78,72360,DB00126,Vitamin C
,22127588,total body clearance,"Ascorbic acid (200 mg/kg) altered colistin pharmacokinetics, as the total body clearance decreased from 3.78 ± 0.36 mL/min/kg (colistin group) to 2.46 ± 0.57 mL/min/kg (P = 0.0024).",Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22127588/),[ml] / [kg·min],2.46,72361,DB00126,Vitamin C
,21803667,absolute bioavailability,"This validated method was successfully applied to the preliminary pharmacokinetic study of SF in rats for the first time, and the absolute bioavailability of SF was found to be only 0.22 ± 0.15%.",A rapid and sensitive HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of sibiricaxanthone F in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21803667/),%,0.22,75272,DB00126,Vitamin C
,9415641,AUC,"The plasma [14C] AUC and CLr(app) were similar between patients and controls [AUC patient mean (standard deviation, SD) = 37.1 (6.8), AUC control mean (SD) = 38.6 (9.9), p = 0.74; CLr(app) patient mean (SD) = 0.57 (0.24), CLr(app) control mean (SD) = 0.47 (0.27), p = 0.45].",Ascorbic acid absorption in patients with systemic sclerosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9415641/),,38.6,79899,DB00126,Vitamin C
,24284610,Urinary excretion,"Urinary excretion was calculated as ~40% and ~50% of the ingested dose from the vitamin C tablet and kiwifruit arms, respectively.",A randomised cross-over pharmacokinetic bioavailability study of synthetic versus kiwifruit-derived vitamin C. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24284610/),%,40,80551,DB00126,Vitamin C
,24284610,Urinary excretion,"Urinary excretion was calculated as ~40% and ~50% of the ingested dose from the vitamin C tablet and kiwifruit arms, respectively.",A randomised cross-over pharmacokinetic bioavailability study of synthetic versus kiwifruit-derived vitamin C. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24284610/),%,50,80552,DB00126,Vitamin C
,18446840,Vs,The pharmacokinetic parameters were analysed by WinNonLin (Vs 5.0.1.) using a non-compartmental approach.,Effect of nutrient mixture and black grapes on the pharmacokinetics of orally administered (-)epigallocatechin-3-gallate from green tea extract: a human study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446840/),,5.0.1.,81394,DB00126,Vitamin C
,12720586,"area under curve, AUC 0-infinity","There were no significant effects of smoking or supplementation on relative bioavailability (difference in area under curve, AUC 0-infinity) of erythorbic acid (smokers 357 (sd 119), non-smokers 414 (sd 142) micromol.h/l; P=0.34).",Effect of smoking on erythorbic acid pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12720586/),[h·μM] / [l],357,86316,DB00126,Vitamin C
,12720586,"area under curve, AUC 0-infinity","There were no significant effects of smoking or supplementation on relative bioavailability (difference in area under curve, AUC 0-infinity) of erythorbic acid (smokers 357 (sd 119), non-smokers 414 (sd 142) micromol.h/l; P=0.34).",Effect of smoking on erythorbic acid pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12720586/),[h·μM] / [l],414,86317,DB00126,Vitamin C
,8053973,iron utilization rate,"When given 100 or 300 mg Fe/d Fe-PM together with meal, 3 out of 6 patients showed a higher iron utilization rate (3.4-11.9%/d) than given without meal (0.5-7.5%/d).",Bioavailability of iron from oral ferric polymaltose in humans. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053973/),[%] / [d],3.4-11.9,88236,DB00126,Vitamin C
,8053973,iron utilization rate,"When given 100 or 300 mg Fe/d Fe-PM together with meal, 3 out of 6 patients showed a higher iron utilization rate (3.4-11.9%/d) than given without meal (0.5-7.5%/d).",Bioavailability of iron from oral ferric polymaltose in humans. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053973/),[%] / [d],0.5-7.5,88237,DB00126,Vitamin C
,26854847,Cmax,"Cmax, Tmax, and area under the curve (AUC) of flavanols in plasma after consumption of GTVX were 5980.58 μg/mL, 2.14 h, and 18,915.56 h·μg/mL, respectively, indicating that GTVX showed significantly higher AUC than GT (13,855.43 μg/mL).",Pharmacokinetics and Plasma Cellular Antioxidative Effects of Flavanols After Oral Intake of Green Tea Formulated with Vitamin C and Xylitol in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854847/),[μg] / [ml],5980.58,89747,DB00126,Vitamin C
,26854847,Tmax,"Cmax, Tmax, and area under the curve (AUC) of flavanols in plasma after consumption of GTVX were 5980.58 μg/mL, 2.14 h, and 18,915.56 h·μg/mL, respectively, indicating that GTVX showed significantly higher AUC than GT (13,855.43 μg/mL).",Pharmacokinetics and Plasma Cellular Antioxidative Effects of Flavanols After Oral Intake of Green Tea Formulated with Vitamin C and Xylitol in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854847/),h,2.14,89748,DB00126,Vitamin C
,26854847,area under the curve (AUC),"Cmax, Tmax, and area under the curve (AUC) of flavanols in plasma after consumption of GTVX were 5980.58 μg/mL, 2.14 h, and 18,915.56 h·μg/mL, respectively, indicating that GTVX showed significantly higher AUC than GT (13,855.43 μg/mL).",Pharmacokinetics and Plasma Cellular Antioxidative Effects of Flavanols After Oral Intake of Green Tea Formulated with Vitamin C and Xylitol in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854847/),[h·μg] / [ml],"18,915.56",89749,DB00126,Vitamin C
,26854847,AUC,"Cmax, Tmax, and area under the curve (AUC) of flavanols in plasma after consumption of GTVX were 5980.58 μg/mL, 2.14 h, and 18,915.56 h·μg/mL, respectively, indicating that GTVX showed significantly higher AUC than GT (13,855.43 μg/mL).",Pharmacokinetics and Plasma Cellular Antioxidative Effects of Flavanols After Oral Intake of Green Tea Formulated with Vitamin C and Xylitol in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26854847/),[μg] / [ml],"13,855.43",89750,DB00126,Vitamin C
,31173997,flow rate,"WA was isolated on a Hypurity C18 (50 × 4.6 mm, 5 μm) column by isocratic elution at a flow rate of 0.5 mL/min using acetonitrile and water as the mobile phase (35:65, v/v).",Liquid chromatography-tandem mass spectrometry to assess the pharmacokinetics and tissue distribution of withaferin A in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31173997/),[ml] / [min],0.5,91943,DB00126,Vitamin C
,31173997,retention time,The retention time was 4 min.,Liquid chromatography-tandem mass spectrometry to assess the pharmacokinetics and tissue distribution of withaferin A in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31173997/),min,4,91944,DB00126,Vitamin C
,31173997,m,Quantification was performed through multiple reaction monitoring (MRM) modes of m/z 471.1 → 281 for WA and m/z 488.1 → 263 for IS in the positive-ion mode.,Liquid chromatography-tandem mass spectrometry to assess the pharmacokinetics and tissue distribution of withaferin A in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31173997/),,471.,91945,DB00126,Vitamin C
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,"0,63-1,00",97122,DB00126,Vitamin C
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,"0,85",97123,DB00126,Vitamin C
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,0.62-1.22,97124,DB00126,Vitamin C
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,0.84,97125,DB00126,Vitamin C
,28710938,ethanol,"The ethanol elimination rates were 0.16‰/h (0.14-0.19‰/h) and 0.17‰/h (0.14-0.22 ‰/h) in the placebo and ""Eezup!"" condition without significant difference.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),[‰] / [h],0.16,97126,DB00126,Vitamin C
,28710938,elimination rates,"The ethanol elimination rates were 0.16‰/h (0.14-0.19‰/h) and 0.17‰/h (0.14-0.22 ‰/h) in the placebo and ""Eezup!"" condition without significant difference.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),[‰] / [h],0.16,97127,DB00126,Vitamin C
,28710938,elimination rates,"The ethanol elimination rates were 0.16‰/h (0.14-0.19‰/h) and 0.17‰/h (0.14-0.22 ‰/h) in the placebo and ""Eezup!"" condition without significant difference.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),[‰] / [h],0.17,97128,DB00126,Vitamin C
up to,6283699,max.,"The injection of free catecholestrogens resulted in bolus-like elevations of the serum and tissue concentrations of the respective compound (max. values up to 9 ng/ml, half-life below 1 h) whereas the injection of catecholestrogen benzoates gave lower (max. values about 1 ng/ml) but prolonged elevations (half-life approx.",Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283699/),[ng] / [ml],9,107151,DB00126,Vitamin C
below,6283699,half-life,"The injection of free catecholestrogens resulted in bolus-like elevations of the serum and tissue concentrations of the respective compound (max. values up to 9 ng/ml, half-life below 1 h) whereas the injection of catecholestrogen benzoates gave lower (max. values about 1 ng/ml) but prolonged elevations (half-life approx.",Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283699/),h,1,107152,DB00126,Vitamin C
,6283699,max.,"The injection of free catecholestrogens resulted in bolus-like elevations of the serum and tissue concentrations of the respective compound (max. values up to 9 ng/ml, half-life below 1 h) whereas the injection of catecholestrogen benzoates gave lower (max. values about 1 ng/ml) but prolonged elevations (half-life approx.",Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283699/),[ng] / [ml],1,107153,DB00126,Vitamin C
,16085104,metabolic clearance,"The pre-operative metabolic clearance was 7.6 +/- 2.22 l/h (mean +/- SD), increasing significantly to 12.1 +/- 4.87 l/h on the first post-operative day (P < 0.001).",Metabolic clearance of the antioxidant ascorbic acid in surgical patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085104/),[l] / [h],7.6,109907,DB00126,Vitamin C
,16085104,metabolic clearance,"The pre-operative metabolic clearance was 7.6 +/- 2.22 l/h (mean +/- SD), increasing significantly to 12.1 +/- 4.87 l/h on the first post-operative day (P < 0.001).",Metabolic clearance of the antioxidant ascorbic acid in surgical patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085104/),[l] / [h],12.1,109908,DB00126,Vitamin C
,17567733,apparent terminal elimination half-life,The apparent terminal elimination half-life of the total radioactivity was 72 h.,"Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17567733/),h,72,110682,DB00126,Vitamin C
,12739983,elimination half-life (t((1/2))),Vitamin C is not protein-bound and is eliminated with an elimination half-life (t((1/2))) of 10 hours.,Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,10,111974,DB00126,Vitamin C
,12739983,bioavailability,"The bioavailability of all-rac-alpha-tocopherol is estimated to be 50% of R,R,R-alpha-tocopherol.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),%,50,111975,DB00126,Vitamin C
,12739983,t((1/2)),"Elimination of alpha-tocopherol takes several days with a t((1/2)) of 81 and 73 hours for R,R,R-alpha-tocopherol and all-rac-alpha-tocopherol, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,81,111976,DB00126,Vitamin C
,12739983,t((1/2)),"Elimination of alpha-tocopherol takes several days with a t((1/2)) of 81 and 73 hours for R,R,R-alpha-tocopherol and all-rac-alpha-tocopherol, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,73,111977,DB00126,Vitamin C
,12739983,t((1/2)),"The t((1/2)) of tocotrienols is short, ranging from 3.8-4.4 hours for gamma- and alpha-tocotrienol, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,3.8-4.4,111978,DB00126,Vitamin C
,12739983,t((1/2)),"Elimination of carotenoids takes several days with a t((1/2)) of 5-7 and 2-3 days for beta-carotene and lycopene, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),d,5-7,111979,DB00126,Vitamin C
,12739983,t((1/2)),"Elimination of carotenoids takes several days with a t((1/2)) of 5-7 and 2-3 days for beta-carotene and lycopene, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),d,2-3,111980,DB00126,Vitamin C
,12739983,bioconversion,"The bioconversion of beta-carotene to retinal is dose-dependent, and ranges between 27% and 2% for a 6 and 126mg dose, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),%,27,111981,DB00126,Vitamin C
,12739983,bioconversion,"The bioconversion of beta-carotene to retinal is dose-dependent, and ranges between 27% and 2% for a 6 and 126mg dose, respectively.",Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),%,2,111982,DB00126,Vitamin C
,12739983,t((1/2)),The t((1/2)) ranges from 12-19 hours.,Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,12-19,111983,DB00126,Vitamin C
,12739983,t((1/2)),The bioavailabillity of catechins is low and they are eliminated with a t((1/2)) of 2-4 hours.,Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739983/),h,2-4,111984,DB00126,Vitamin C
,9356534,steady state plasma concentration,"For example, when the daily dose is increased from 200 to 2500 mg (from 1.1 to 14.2 mmol) the mean steady state plasma concentration increases only from approximately 12 to 15 mg/L (from 68.1 to 85.2 mumol/L).",Pharmacokinetic perspectives on megadoses of ascorbic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356534/),[mg] / [l],12 to 15,117557,DB00126,Vitamin C
,9356534,steady state plasma concentration,"For example, when the daily dose is increased from 200 to 2500 mg (from 1.1 to 14.2 mmol) the mean steady state plasma concentration increases only from approximately 12 to 15 mg/L (from 68.1 to 85.2 mumol/L).",Pharmacokinetic perspectives on megadoses of ascorbic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356534/),[μM] / [l],68.1 to 85.2,117558,DB00126,Vitamin C
,9374798,plasma clearance (Cl),"After a radiolabeled AA intravenous administration, the plasma clearance (Cl) was low (40.8 +/- 9.5 ml.kg-1.h-1), the steady-state volume of distribution (Vss) was very high (8.9 +/- 2.2 l/kg), and the AA mean residence time (MRT) was long (230 +/- 85 h).",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),[ml] / [h·kg],40.8,119562,DB00126,Vitamin C
,9374798,steady-state volume of distribution (Vss),"After a radiolabeled AA intravenous administration, the plasma clearance (Cl) was low (40.8 +/- 9.5 ml.kg-1.h-1), the steady-state volume of distribution (Vss) was very high (8.9 +/- 2.2 l/kg), and the AA mean residence time (MRT) was long (230 +/- 85 h).",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),[l] / [kg],8.9,119563,DB00126,Vitamin C
,9374798,mean residence time (MRT),"After a radiolabeled AA intravenous administration, the plasma clearance (Cl) was low (40.8 +/- 9.5 ml.kg-1.h-1), the steady-state volume of distribution (Vss) was very high (8.9 +/- 2.2 l/kg), and the AA mean residence time (MRT) was long (230 +/- 85 h).",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),h,230,119564,DB00126,Vitamin C
,9374798,Cl,"After administration of a 3-g dose of AA, the Cl was high (450 +/- 146 ml.kg-1.h-1), the Vss was low (0.658 +/- 0.236 l/kg), and the MRT was short (1.49 +/- 0.41 h), indicating a strong nonlinearity of AA disposition in calves and the impossibility of preventing scurvy with the use of a loading AA dose.",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),[ml] / [h·kg],450,119565,DB00126,Vitamin C
,9374798,Vss,"After administration of a 3-g dose of AA, the Cl was high (450 +/- 146 ml.kg-1.h-1), the Vss was low (0.658 +/- 0.236 l/kg), and the MRT was short (1.49 +/- 0.41 h), indicating a strong nonlinearity of AA disposition in calves and the impossibility of preventing scurvy with the use of a loading AA dose.",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),[l] / [kg],0.658,119566,DB00126,Vitamin C
,9374798,MRT,"After administration of a 3-g dose of AA, the Cl was high (450 +/- 146 ml.kg-1.h-1), the Vss was low (0.658 +/- 0.236 l/kg), and the MRT was short (1.49 +/- 0.41 h), indicating a strong nonlinearity of AA disposition in calves and the impossibility of preventing scurvy with the use of a loading AA dose.",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),h,1.49,119567,DB00126,Vitamin C
,9374798,body pool size,The estimated AA body pool size was 23.1 +/- 6.8 mg/kg.,Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),[mg] / [kg],23.1,119568,DB00126,Vitamin C
,9374798,entry rate,"The average daily AA entry rate over the first 7 days of life was 3.43 +/- 1.16 mg/kg, and it is suggested that the calf is able to synthesize AA at an early stage.",Ascorbic acid disposition kinetics in the plasma and tissues of calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374798/),[mg] / [kg],3.43,119569,DB00126,Vitamin C
,33336364,solubility,"The solubility of DMY at pH 3-5 was about 750 μg mL-1 , slightly increasing to 853 μg mL-1 at pH 6.",Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336364/),[μg] / [ml],750,122149,DB00126,Vitamin C
,33336364,solubility,"The solubility of DMY at pH 3-5 was about 750 μg mL-1 , slightly increasing to 853 μg mL-1 at pH 6.",Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336364/),[μg] / [ml],853,122150,DB00126,Vitamin C
,33336364,bioavailability,Pharmacokinetic studies showed that the bioavailability of DMY increased from 0.122% to 0.341% by supplementing with AA (10% of DMY).,Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336364/),%,0.122,122151,DB00126,Vitamin C
,33336364,bioavailability,Pharmacokinetic studies showed that the bioavailability of DMY increased from 0.122% to 0.341% by supplementing with AA (10% of DMY).,Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336364/),%,0.341,122152,DB00126,Vitamin C
,33336364,bioavailability,Pharmacokinetic studies showed that the bioavailability of DMY increased from 0.122% to 0.341% by supplementing with AA (10% of DMY).,Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336364/),%,10,122153,DB00126,Vitamin C
,6726482,t1/2,Excretion analysis indicated t1/2 = 42 days.,"Distribution of ascorbate-2-sulfate and distribution, half-life and turnover rates of [1-14C]ascorbic acid in rainbow trout. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726482/),d,42,123294,DB00126,Vitamin C
,6726482,C1,Estimates of body pool for C1 are 27-29 mg/kg.,"Distribution of ascorbate-2-sulfate and distribution, half-life and turnover rates of [1-14C]ascorbic acid in rainbow trout. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726482/),[mg] / [kg],27-29,123295,DB00126,Vitamin C
,15068981,peak plasma concentrations,Vitamin C at a dose of 1.25 g administered orally produced mean (+/-sd) peak plasma concentrations of 134.8 +/- 20.6 micromol/L compared with 885 +/- 201.2 micromol/L for intravenous administration.,Vitamin C pharmacokinetics: implications for oral and intravenous use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15068981/),[μM] / [l],134.8,123926,DB00126,Vitamin C
,15068981,peak plasma concentrations,Vitamin C at a dose of 1.25 g administered orally produced mean (+/-sd) peak plasma concentrations of 134.8 +/- 20.6 micromol/L compared with 885 +/- 201.2 micromol/L for intravenous administration.,Vitamin C pharmacokinetics: implications for oral and intravenous use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15068981/),[μM] / [l],885,123927,DB00126,Vitamin C
,15068981,peak plasma vitamin C concentrations,"For the maximum tolerated oral dose of 3 g every 4 hours, pharmacokinetic modeling predicted peak plasma vitamin C concentrations of 220 micromol/L and 13 400 micromol/L for a 50-g intravenous dose.",Vitamin C pharmacokinetics: implications for oral and intravenous use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15068981/),[μM] / [l],220,123928,DB00126,Vitamin C
,15068981,peak plasma vitamin C concentrations,"For the maximum tolerated oral dose of 3 g every 4 hours, pharmacokinetic modeling predicted peak plasma vitamin C concentrations of 220 micromol/L and 13 400 micromol/L for a 50-g intravenous dose.",Vitamin C pharmacokinetics: implications for oral and intravenous use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15068981/),[μM] / [l],13 400,123929,DB00126,Vitamin C
,6704506,plasma half-life,The mean plasma half-life of antipyrine was 10.2 h and the mean plasma clearance was 2.561 h-1 1.73 m-2 before vitamin C restriction.,The influence of vitamin C on antipyrine pharmacokinetics in elderly men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704506/),h,10.2,127087,DB00126,Vitamin C
,6704506,plasma clearance,The mean plasma half-life of antipyrine was 10.2 h and the mean plasma clearance was 2.561 h-1 1.73 m-2 before vitamin C restriction.,The influence of vitamin C on antipyrine pharmacokinetics in elderly men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704506/),[1.73] / [(m)^2·h],2.561,127088,DB00126,Vitamin C
,3199063,plasma half-life,The plasma half-life of the LH bioactivity (with 95% confidence limits) was estimated to be 42.4 (35.3-49.5) min for IRP 68/40 and 41.3 (31.5-51.0) min for IRP 78/549.,Plasma clearance in the rat of the LH bioactivity of two human LH standards of differing molecular composition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199063/),min,42.4,130728,DB00126,Vitamin C
,3199063,plasma half-life,The plasma half-life of the LH bioactivity (with 95% confidence limits) was estimated to be 42.4 (35.3-49.5) min for IRP 68/40 and 41.3 (31.5-51.0) min for IRP 78/549.,Plasma clearance in the rat of the LH bioactivity of two human LH standards of differing molecular composition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199063/),min,41.3,130729,DB00126,Vitamin C
,7589058,maximum concentration,"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[nM] / [l],463,135269,DB00126,Vitamin C
,7589058,maximum concentration,"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[nM] / [l],33,135270,DB00126,Vitamin C
,7589058,area under the propranolol concentration-time curve (from 0 to 24 hours),"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[h·μM] / [l],3.13,135271,DB00126,Vitamin C
,7589058,area under the propranolol concentration-time curve (from 0 to 24 hours),"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[h·μM] / [l],1.96,135272,DB00126,Vitamin C
,7589058,time to reach maximum propranolol concentration,The time to reach maximum propranolol concentration was increased from 1.9 to 2.7.,Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),,1.9,135273,DB00126,Vitamin C
,7589058,time to reach maximum propranolol concentration,The time to reach maximum propranolol concentration was increased from 1.9 to 2.7.,Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),,2.7,135274,DB00126,Vitamin C
,7589058,total amount of drug recovered,The total amount of drug recovered in urine has also significantly diminished (from 12.6 to 4.29 mg).,Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),mg,12.6,135275,DB00126,Vitamin C
,14581068,flow rate,"All-trans RA, 9-cRA, and 13-cRA were well separated from each other in plasma by using a C18 precolumn and a column with a gradient solvent system of mobile phases A and B at a flow rate of 1.0 ml/min.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),[ml] / [min],1.0,138219,DB00126,Vitamin C
,14581068,C,"C to inhibit the interconversion were 50 and 150 microM, respectively, (2) higher concentrations of NEM and Vit.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),μM,50,138220,DB00126,Vitamin C
,14581068,C,"C to inhibit the interconversion were 50 and 150 microM, respectively, (2) higher concentrations of NEM and Vit.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),μM,150,138221,DB00126,Vitamin C
,14581068,recovery,"C were required to prevent the interconversion at higher temperature, (3) the precision and accuracy of calibration curve with various concentration of tRA (1-1000 ng/ml) and 13-cRA (5-800 ng/ml) in plasma showed good linearity (r(2)=0.9992 and 0.9994), and between-day errors expressed by coefficient of variation (CV, %) for tRA and 13-cRA which were both less than 5.6%, (4) the mean recovery of the analytes were 78-94% for tRA and 80-92% for 13-cRA at concentration range from 1 to 1000 ng/ml and 5 to 800 ng/ml, respectively, and (5) the limit of quantitation of tRA and 13-cRA were 1 and 5 ng/ml, respectively.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),%,78-94,138222,DB00126,Vitamin C
,14581068,recovery,"C were required to prevent the interconversion at higher temperature, (3) the precision and accuracy of calibration curve with various concentration of tRA (1-1000 ng/ml) and 13-cRA (5-800 ng/ml) in plasma showed good linearity (r(2)=0.9992 and 0.9994), and between-day errors expressed by coefficient of variation (CV, %) for tRA and 13-cRA which were both less than 5.6%, (4) the mean recovery of the analytes were 78-94% for tRA and 80-92% for 13-cRA at concentration range from 1 to 1000 ng/ml and 5 to 800 ng/ml, respectively, and (5) the limit of quantitation of tRA and 13-cRA were 1 and 5 ng/ml, respectively.",Novel inhibition of cis/trans retinoic acid interconversion in biological fluids--an accurate method for determination of trans and 13-cis retinoic acid in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581068/),%,80-92,138223,DB00126,Vitamin C
,3566867,net-Hb,"Haemoglobin (Hb) regeneration after 100 mg of iron as Fe (III)-complex and Fe (II)-sulphate administered during 28 days with meals amounted to a mean of 0.68 +/- 0.2 g/l and 1.1 +/- 0.3 g/l (means +/- SD) of total daily Hb-increase and a net-Hb-increase of 0.31 +/- 0.37 g/l and 0.79 +/- 0.36 g/l (means +/- SD), respectively.",Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566867/),[g] / [l],0.31,141327,DB00126,Vitamin C
,3566867,net-Hb,"Haemoglobin (Hb) regeneration after 100 mg of iron as Fe (III)-complex and Fe (II)-sulphate administered during 28 days with meals amounted to a mean of 0.68 +/- 0.2 g/l and 1.1 +/- 0.3 g/l (means +/- SD) of total daily Hb-increase and a net-Hb-increase of 0.31 +/- 0.37 g/l and 0.79 +/- 0.36 g/l (means +/- SD), respectively.",Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566867/),[g] / [l],0.79,141328,DB00126,Vitamin C
,15635356,AUC,"AUC analyses for the first 128 hours postdosing; 2.93+/-1.93, 5.37+/-5.0, and 4.11+/-3.04 micromol .",Lutein absorption is facilitated with cosupplementation of ascorbic acid in young adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15635356/),μM,2.93,143745,DB00126,Vitamin C
,15635356,AUC,"AUC analyses for the first 128 hours postdosing; 2.93+/-1.93, 5.37+/-5.0, and 4.11+/-3.04 micromol .",Lutein absorption is facilitated with cosupplementation of ascorbic acid in young adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15635356/),μM,5.37,143746,DB00126,Vitamin C
,15635356,AUC,"AUC analyses for the first 128 hours postdosing; 2.93+/-1.93, 5.37+/-5.0, and 4.11+/-3.04 micromol .",Lutein absorption is facilitated with cosupplementation of ascorbic acid in young adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15635356/),μM,4.11,143747,DB00126,Vitamin C
,21863748,Cmax,"In the case of diclofenak treatment without vitamins Cmax corresponds to 1137.2 +/- 82.4 ng/ml, with 2 tablets of Gitagamp--Cmax 1326.7 +/- 122.5 ng/ml, and with 4 tablets--Cmax 2200.4 +/- 111.3 ng/ml.",[The influence of vitamin B group on monooxygenase activity of cytochrome P450 3A4: pharmacokinetics and electro analysis of catalytic properties]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863748/),[ng] / [ml],1137.2,155382,DB00126,Vitamin C
,21863748,Cmax,"In the case of diclofenak treatment without vitamins Cmax corresponds to 1137.2 +/- 82.4 ng/ml, with 2 tablets of Gitagamp--Cmax 1326.7 +/- 122.5 ng/ml, and with 4 tablets--Cmax 2200.4 +/- 111.3 ng/ml.",[The influence of vitamin B group on monooxygenase activity of cytochrome P450 3A4: pharmacokinetics and electro analysis of catalytic properties]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863748/),[ng] / [ml],1326.7,155383,DB00126,Vitamin C
,21863748,Cmax,"In the case of diclofenak treatment without vitamins Cmax corresponds to 1137.2 +/- 82.4 ng/ml, with 2 tablets of Gitagamp--Cmax 1326.7 +/- 122.5 ng/ml, and with 4 tablets--Cmax 2200.4 +/- 111.3 ng/ml.",[The influence of vitamin B group on monooxygenase activity of cytochrome P450 3A4: pharmacokinetics and electro analysis of catalytic properties]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863748/),[ng] / [ml],2200.4,155384,DB00126,Vitamin C
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"1,3",155977,DB00126,Vitamin C
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"2,1",155978,DB00126,Vitamin C
,31096937,objective response rate,"The objective response rate was 58.3%, and the disease control rate was 95.8%.",Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096937/),%,58.3,157778,DB00126,Vitamin C
,31096937,disease control rate,"The objective response rate was 58.3%, and the disease control rate was 95.8%.",Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096937/),,95,157779,DB00126,Vitamin C
,23596161,absorption,"The absorption of (57)Fe from the modified meal, compared with regular meal, was significantly (P < 0.05) greater in both girls (23.9 ± 11.2 vs. 9.7 ± 6.5%) and boys (19.2 ± 8.4 vs. 8.6 ± 4.1%).",Inclusion of guava enhances non-heme iron bioavailability but not fractional zinc absorption from a rice-based meal in adolescents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596161/),%,23.9,162265,DB00126,Vitamin C
,23596161,absorption,"The absorption of (57)Fe from the modified meal, compared with regular meal, was significantly (P < 0.05) greater in both girls (23.9 ± 11.2 vs. 9.7 ± 6.5%) and boys (19.2 ± 8.4 vs. 8.6 ± 4.1%).",Inclusion of guava enhances non-heme iron bioavailability but not fractional zinc absorption from a rice-based meal in adolescents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596161/),%,9.7,162266,DB00126,Vitamin C
,23596161,absorption,"The absorption of (57)Fe from the modified meal, compared with regular meal, was significantly (P < 0.05) greater in both girls (23.9 ± 11.2 vs. 9.7 ± 6.5%) and boys (19.2 ± 8.4 vs. 8.6 ± 4.1%).",Inclusion of guava enhances non-heme iron bioavailability but not fractional zinc absorption from a rice-based meal in adolescents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596161/),%,19.2,162267,DB00126,Vitamin C
,23596161,absorption,"The absorption of (57)Fe from the modified meal, compared with regular meal, was significantly (P < 0.05) greater in both girls (23.9 ± 11.2 vs. 9.7 ± 6.5%) and boys (19.2 ± 8.4 vs. 8.6 ± 4.1%).",Inclusion of guava enhances non-heme iron bioavailability but not fractional zinc absorption from a rice-based meal in adolescents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596161/),%,8.6,162268,DB00126,Vitamin C
,14728990,T(max),"Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated.",Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),h,1-4,164954,DB00126,Vitamin C
,14728990,C(max),"Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated.",Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),[nM] / [l],258.7-259.0,164955,DB00126,Vitamin C
,14728990,area under the curve (AUC,"Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated.",Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),[)h·nmol(] / [l],1708-1958,164956,DB00126,Vitamin C
,14728990,elimination half-life time,The elimination half-life time was calculated to be 3.3-5.1h.,Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),h,3.3-5.1,164957,DB00126,Vitamin C
,33489687,IC50,"Compound CE48 exhibited better anti-tyrosinase (IC50-29.64 μM) and antioxidant (EC50-12.67 μM) activity than the reference compounds, kojic acid (IC50-50.30 μM) and ascorbic acid (EC50-14.55 μM), respectively.",Bioevaluation and molecular docking analysis of novel phenylpropanoid derivatives as potent food preservative and anti-microbials. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33489687/),μM,29.64,167937,DB00126,Vitamin C
,33489687,EC50,"Compound CE48 exhibited better anti-tyrosinase (IC50-29.64 μM) and antioxidant (EC50-12.67 μM) activity than the reference compounds, kojic acid (IC50-50.30 μM) and ascorbic acid (EC50-14.55 μM), respectively.",Bioevaluation and molecular docking analysis of novel phenylpropanoid derivatives as potent food preservative and anti-microbials. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33489687/),μM,12.67,167938,DB00126,Vitamin C
,33489687,IC50,"Compound CE48 exhibited better anti-tyrosinase (IC50-29.64 μM) and antioxidant (EC50-12.67 μM) activity than the reference compounds, kojic acid (IC50-50.30 μM) and ascorbic acid (EC50-14.55 μM), respectively.",Bioevaluation and molecular docking analysis of novel phenylpropanoid derivatives as potent food preservative and anti-microbials. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33489687/),μM,50.30,167939,DB00126,Vitamin C
,33489687,EC50,"Compound CE48 exhibited better anti-tyrosinase (IC50-29.64 μM) and antioxidant (EC50-12.67 μM) activity than the reference compounds, kojic acid (IC50-50.30 μM) and ascorbic acid (EC50-14.55 μM), respectively.",Bioevaluation and molecular docking analysis of novel phenylpropanoid derivatives as potent food preservative and anti-microbials. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33489687/),μM,14.55,167940,DB00126,Vitamin C
,33489687,gut-blood barrier permeability,"In silico absorption, distribution, metabolism, excretion/toxicity (ADME/T) and toxicological studies of these newly synthesized compounds exhibited acceptable pharmacokinetic and safety profiles, like good aqueous solubility (- 3.34 to - 7.57), low human oral absorption (e.g., SAM30, SE78, FAM34), low gut-blood barrier permeability [36.67-209.88 nm/s in Cancer coli-2 (Caco-2) cells] and [19.45-91.51 nm/s in Madin-Darby Canine Kidney (MDCK) cells], low blood-brain barrier penetration, non-mutagenicity, and non-carcinogenicity.",Bioevaluation and molecular docking analysis of novel phenylpropanoid derivatives as potent food preservative and anti-microbials. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33489687/),[nm] / [s],36.67-209.88,167941,DB00126,Vitamin C
,33489687,gut-blood barrier permeability,"In silico absorption, distribution, metabolism, excretion/toxicity (ADME/T) and toxicological studies of these newly synthesized compounds exhibited acceptable pharmacokinetic and safety profiles, like good aqueous solubility (- 3.34 to - 7.57), low human oral absorption (e.g., SAM30, SE78, FAM34), low gut-blood barrier permeability [36.67-209.88 nm/s in Cancer coli-2 (Caco-2) cells] and [19.45-91.51 nm/s in Madin-Darby Canine Kidney (MDCK) cells], low blood-brain barrier penetration, non-mutagenicity, and non-carcinogenicity.",Bioevaluation and molecular docking analysis of novel phenylpropanoid derivatives as potent food preservative and anti-microbials. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33489687/),[nm] / [s],19.45-91.51,167942,DB00126,Vitamin C
,16567755,peak plasma concentrations,"Recent evidence shows that oral administration of the maximum tolerated dose of vitamin C (18 g/d) produces peak plasma concentrations of only 220 micromol/L, whereas intravenous administration of the same dose produces plasma concentrations about 25-fold higher.",Intravenously administered vitamin C as cancer therapy: three cases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567755/),[μM] / [l],220,171747,DB00126,Vitamin C
,15173412,lag time,"Although absorbed oat phenolics did not enhance ex vivo resistance of LDL to Cu(2+)-induced oxidation, in vitro addition of ascorbic acid synergistically extended the lag time of the 60-min sample from 137 to 216 min (P < or = 0.05), unmasking the bioactivity of the oat phenolics from the oral dose.",Avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173412/),min,137 to 216,177576,DB00126,Vitamin C
,9204776,Peak plasma levels,Peak plasma levels of PI after oral administration of PY were measured after 105 +/- 37 min showing an average concentration of 8.2 +/- 2.8 ng PI/ml plasma.,Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204776/),ng,8.2,180343,DB00126,Vitamin C
,9204776,peak concentrations,4HIAA peak concentrations of 150 +/- 61 ng/ml plasma were found 113 +/- 41 min after ingestion of PY.,Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204776/),[ng] / [ml·plasma],150,180344,DB00126,Vitamin C
,9204776,maximum plasma concentration,"After intravenous administration, a mean PI maximum plasma concentration of 12.9 +/- 5.6 ng/ml plasma was found 1.9 +/- 1.0 min after injection.",Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204776/),[ng] / [ml·plasma],12.9,180345,DB00126,Vitamin C
,9204776,absolute bioavailability,Estimates for the absolute bioavailability of PI after oral administration of PY were 52.7 +/- 20% (N = 3).,Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204776/),%,52.7,180346,DB00126,Vitamin C
,17205631,la,PPIX fluorescence from the Epidex layers was measured up to 150 h after the precursor administration using a microspectrofluorometer (lambda(ex): 400 +/- 20 nm; lambda(det): 635 nm).,On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl ester derivative tested on an epidermal equivalent of human skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205631/),nm,400,181060,DB00126,Vitamin C
,17205631,decay half life,"The decay half life measured for PPIX fluorescence is 30 and 42.5 h, respectively, for ALA and h-ALA.",On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl ester derivative tested on an epidermal equivalent of human skin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205631/),h,30,181061,DB00126,Vitamin C
,17205631,decay half life,"The decay half life measured for PPIX fluorescence is 30 and 42.5 h, respectively, for ALA and h-ALA.",On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl ester derivative tested on an epidermal equivalent of human skin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205631/),h,42.5,181062,DB00126,Vitamin C
,8998559,extraction efficiencies,The extraction efficiencies of MTO are 60% in whole blood and 38% in tissue homogenates.,Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998559/),%,60,184524,DB00126,Vitamin C
,8998559,extraction efficiencies,The extraction efficiencies of MTO are 60% in whole blood and 38% in tissue homogenates.,Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8998559/),%,38,184525,DB00126,Vitamin C
,12235651,Cltot,"No significant change in Cltot was observed for tumor patients (median and 25th and 75th percentiles: 11.5, 8.0, and 14.0 l/h) compared with volunteers (median and 25th and 75th percentiles: 11.3, 9.9, and 13.2 l/h).",Clearance of ascorbic acid in plasma in patients before major maxillofacial surgery compared with that in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235651/),[l] / [h],11.5,185347,DB00126,Vitamin C
,12235651,Cltot,"No significant change in Cltot was observed for tumor patients (median and 25th and 75th percentiles: 11.5, 8.0, and 14.0 l/h) compared with volunteers (median and 25th and 75th percentiles: 11.3, 9.9, and 13.2 l/h).",Clearance of ascorbic acid in plasma in patients before major maxillofacial surgery compared with that in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235651/),[l] / [h],8.0,185348,DB00126,Vitamin C
,12235651,Cltot,"No significant change in Cltot was observed for tumor patients (median and 25th and 75th percentiles: 11.5, 8.0, and 14.0 l/h) compared with volunteers (median and 25th and 75th percentiles: 11.3, 9.9, and 13.2 l/h).",Clearance of ascorbic acid in plasma in patients before major maxillofacial surgery compared with that in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235651/),[l] / [h],14.0,185349,DB00126,Vitamin C
,12235651,Cltot,"No significant change in Cltot was observed for tumor patients (median and 25th and 75th percentiles: 11.5, 8.0, and 14.0 l/h) compared with volunteers (median and 25th and 75th percentiles: 11.3, 9.9, and 13.2 l/h).",Clearance of ascorbic acid in plasma in patients before major maxillofacial surgery compared with that in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235651/),[l] / [h],11.3,185350,DB00126,Vitamin C
,12235651,Cltot,"No significant change in Cltot was observed for tumor patients (median and 25th and 75th percentiles: 11.5, 8.0, and 14.0 l/h) compared with volunteers (median and 25th and 75th percentiles: 11.3, 9.9, and 13.2 l/h).",Clearance of ascorbic acid in plasma in patients before major maxillofacial surgery compared with that in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235651/),[l] / [h],9.9,185351,DB00126,Vitamin C
,12235651,Cltot,"No significant change in Cltot was observed for tumor patients (median and 25th and 75th percentiles: 11.5, 8.0, and 14.0 l/h) compared with volunteers (median and 25th and 75th percentiles: 11.3, 9.9, and 13.2 l/h).",Clearance of ascorbic acid in plasma in patients before major maxillofacial surgery compared with that in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235651/),[l] / [h],13.2,185352,DB00126,Vitamin C
,24101870,half-life,"The liposomes are characterized as stable, with very good pharmacokinetics (half-life 18.6 hours).",Vitamin C-driven epirubicin loading into liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24101870/),h,18.6,186056,DB00126,Vitamin C
,21400028,tumor growth inhibition (TGI),Bortezomib dosed twice-weekly at 0.8 mg/kg IV demonstrated tumor growth inhibition (TGI) of 53.9-58.9%.,"Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21400028/),%,53.9-58.9,187391,DB00126,Vitamin C
,25531873,matrix effect,The matrix effect of normal and hemolyzed plasma was 94.9-101.6%.,Rapid determination of fenoldopam in human plasma by UPLC-MS/MS for pharmacokinetic analysis in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25531873/),%,94.9-101.6,188252,DB00126,Vitamin C
,29258770,IC50,"Compounds 4f (IC50 = 52.0 ± 0.09 µg/ml), 4h (IC50 = 56.0 ± 0.71 µg/ml) and 4l (IC50 = 59.3 ± 0.55 µg/ml) were shown significant antileishmanial when compared with standard sodium stibogluconate (IC50 = 490.0 ± 1.5 µg/ml).",Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],52.0,190714,DB00126,Vitamin C
,29258770,IC50,"Compounds 4f (IC50 = 52.0 ± 0.09 µg/ml), 4h (IC50 = 56.0 ± 0.71 µg/ml) and 4l (IC50 = 59.3 ± 0.55 µg/ml) were shown significant antileishmanial when compared with standard sodium stibogluconate (IC50 = 490.0 ± 1.5 µg/ml).",Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],56.0,190715,DB00126,Vitamin C
,29258770,IC50,"Compounds 4f (IC50 = 52.0 ± 0.09 µg/ml), 4h (IC50 = 56.0 ± 0.71 µg/ml) and 4l (IC50 = 59.3 ± 0.55 µg/ml) were shown significant antileishmanial when compared with standard sodium stibogluconate (IC50 = 490.0 ± 1.5 µg/ml).",Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],59.3,190716,DB00126,Vitamin C
,29258770,IC50,"Compounds 4f (IC50 = 52.0 ± 0.09 µg/ml), 4h (IC50 = 56.0 ± 0.71 µg/ml) and 4l (IC50 = 59.3 ± 0.55 µg/ml) were shown significant antileishmanial when compared with standard sodium stibogluconate (IC50 = 490.0 ± 1.5 µg/ml).",Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],490.0,190717,DB00126,Vitamin C
,29258770,IC50,Antioxidant study revealed that compounds 4i (IC50 = 2.44 ± 0.47 µg/ml) and 4l (IC50 = 3.69 ± 0.44 µg/ml) have shown potent comparable activity when compared with standard ascorbic acid (IC50 = 3.31 ± 0.34 µg/ml).,Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],2.44,190718,DB00126,Vitamin C
,29258770,IC50,Antioxidant study revealed that compounds 4i (IC50 = 2.44 ± 0.47 µg/ml) and 4l (IC50 = 3.69 ± 0.44 µg/ml) have shown potent comparable activity when compared with standard ascorbic acid (IC50 = 3.31 ± 0.34 µg/ml).,Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],3.69,190719,DB00126,Vitamin C
,29258770,IC50,Antioxidant study revealed that compounds 4i (IC50 = 2.44 ± 0.47 µg/ml) and 4l (IC50 = 3.69 ± 0.44 µg/ml) have shown potent comparable activity when compared with standard ascorbic acid (IC50 = 3.31 ± 0.34 µg/ml).,Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29258770/),[μg] / [ml],3.31,190720,DB00126,Vitamin C
,2084130,lower detection limit,The lower detection limit of this assay method was 1 ng.,"Novel assay method for mitoxantrone in plasma, and its application in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084130/),ng,1,193439,DB00126,Vitamin C
,28306207,extract recoveries,"The mean extract recoveries of five flavonoids were 69.1∼89.2%, and the precision and accuracy were within the acceptable limits.",Development and validation of a UHPLC-MS/MS method for the simultaneous determination of five bioactive flavonoids in rat plasma and comparative pharmacokinetic study after oral administration of Xiaochaihu Tang and three compatibilities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28306207/),%,69.1∼89.2,194283,DB00126,Vitamin C
greater,32283195,plasma apparent half-life,"Also, a trend to a higher plasma apparent half-life (greater than24 h) was observed for the oleogel-loaded-CoQ10.",Bioavailability of coenzyme Q10 loaded in an oleogel formulation for oral therapy: Comparison with a commercial-grade solid formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32283195/),h,24,196764,DB00126,Vitamin C
,21258236,degradation half-life,"The overall median degradation half-life of remifentanil was 143 ± (interquartile range) 47 min (minimum, 76 min; maximum, 221 min) without significant differences between very preterm infants (less than 28 gestational weeks) and term infants.",Remifentanil degradation in umbilical cord blood of preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21258236/),min,143,199335,DB00126,Vitamin C
,21258236,degradation half-life,"The overall median degradation half-life of remifentanil was 143 ± (interquartile range) 47 min (minimum, 76 min; maximum, 221 min) without significant differences between very preterm infants (less than 28 gestational weeks) and term infants.",Remifentanil degradation in umbilical cord blood of preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21258236/),min,76,199336,DB00126,Vitamin C
,21258236,degradation half-life,"The overall median degradation half-life of remifentanil was 143 ± (interquartile range) 47 min (minimum, 76 min; maximum, 221 min) without significant differences between very preterm infants (less than 28 gestational weeks) and term infants.",Remifentanil degradation in umbilical cord blood of preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21258236/),min,221,199337,DB00126,Vitamin C
,31778629,Volume of distribution,"Volume of distribution was 23.3 L (IQR, 21.9-27.8 L), clearance 5.2 L/h (IQR, 3.3-5.4 L/h), and half-life 4.3 h (IQR, 2.6-7.5 h).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),l,23.3,200117,DB00126,Vitamin C
,31778629,clearance,"Volume of distribution was 23.3 L (IQR, 21.9-27.8 L), clearance 5.2 L/h (IQR, 3.3-5.4 L/h), and half-life 4.3 h (IQR, 2.6-7.5 h).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),[l] / [h],5.2,200118,DB00126,Vitamin C
,31778629,half-life,"Volume of distribution was 23.3 L (IQR, 21.9-27.8 L), clearance 5.2 L/h (IQR, 3.3-5.4 L/h), and half-life 4.3 h (IQR, 2.6-7.5 h).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),h,4.3,200119,DB00126,Vitamin C
,31778629,T0 concentration,"For the participants who had received at least one dose of intravenous vitamin C before sampling, T0 concentration was 258 μmol/L (IQR, 162- 301 μmol/L).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),[μM] / [l],258,200120,DB00126,Vitamin C
,31778629,volume of distribution,"Pharmacokinetic parameters for subsequent doses were a median volume of distribution 39.9 L (IQR, 31.4-44.4 L), clearance 3.6 L/h (IQR, 2.6-6.5 L/h), and half-life 6.9 h (IQR, 5.7-8.5 h).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),l,39.9,200121,DB00126,Vitamin C
,31778629,clearance,"Pharmacokinetic parameters for subsequent doses were a median volume of distribution 39.9 L (IQR, 31.4-44.4 L), clearance 3.6 L/h (IQR, 2.6-6.5 L/h), and half-life 6.9 h (IQR, 5.7-8.5 h).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),[l] / [h],3.6,200122,DB00126,Vitamin C
,31778629,half-life,"Pharmacokinetic parameters for subsequent doses were a median volume of distribution 39.9 L (IQR, 31.4-44.4 L), clearance 3.6 L/h (IQR, 2.6-6.5 L/h), and half-life 6.9 h (IQR, 5.7-8.5 h).",Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778629/),h,6.9,200123,DB00126,Vitamin C
,25220574,peak plasma AA concentration,The target dose of 60 g AA IV produced a peak plasma AA concentration of 20.3 mM.,Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220574/),mM,20.3,202030,DB00126,Vitamin C
,25220574,Elimination half-life,"Elimination half-life was 1.87 hr (mean, S.D. ± 0.40), volume of distribution 0.19 L/kg (S.D. ±0.05) and clearance rate 6.02 L/hr (100 mL/min).",Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220574/),h,1.87,202031,DB00126,Vitamin C
,25220574,volume of distribution,"Elimination half-life was 1.87 hr (mean, S.D. ± 0.40), volume of distribution 0.19 L/kg (S.D. ±0.05) and clearance rate 6.02 L/hr (100 mL/min).",Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220574/),[l] / [kg],0.19,202032,DB00126,Vitamin C
,25220574,clearance rate,"Elimination half-life was 1.87 hr (mean, S.D. ± 0.40), volume of distribution 0.19 L/kg (S.D. ±0.05) and clearance rate 6.02 L/hr (100 mL/min).",Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220574/),[l] / [h],6.02,202033,DB00126,Vitamin C
,25220574,half-life,A relatively fast first-order elimination with half-life of about 2 hr makes it impossible to maintain AA concentrations in the potential cytotoxic range after infusion stop in prostate cancer patients with normal kidney function.,Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220574/),h,2,202034,DB00126,Vitamin C
,29302210,Cmax,"The area under the curve (AUC) values of calcium ascorbate were 1.5-fold higher than those of ascorbic acid, and the Cmax value of calcium ascorbate (91.0 ng/ml) was higher than that of ascorbic acid (74.8 ng/ml).",Alleviation of ascorbic acid-induced gastric high acidity by calcium ascorbate in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29302210/),[ng] / [ml],91.0,207888,DB00126,Vitamin C
,29302210,Cmax,"The area under the curve (AUC) values of calcium ascorbate were 1.5-fold higher than those of ascorbic acid, and the Cmax value of calcium ascorbate (91.0 ng/ml) was higher than that of ascorbic acid (74.8 ng/ml).",Alleviation of ascorbic acid-induced gastric high acidity by calcium ascorbate in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29302210/),[ng] / [ml],74.8,207889,DB00126,Vitamin C
,7029735,overall half-life,The overall half-life was calculated as 10 - 20 days and is dependent of plasma ascorbate levels.,Metabolism and requirements of ascorbic acid in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029735/),d,10 - 20,207978,DB00126,Vitamin C
,7029735,total turnover,The body pool approached 20 mg/kg body weight at a plasma ascorbate concentration of 0.9 mg/dl and was maintained by a total turnover of 60 mg/d.,Metabolism and requirements of ascorbic acid in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7029735/),[mg] / [d],60,207979,DB00126,Vitamin C
,1315736,half-life,"Since cytochrome c and acetylated cytochrome c disappear from the circulation with a half-life of 4 min, these proteins cannot be used for in vivo detection of superoxide radicals and related metabolites.",Synthesis of a cytochrome c derivative with prolonged in vivo half-life and determination of ascorbyl radicals in the circulation of the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315736/),min,4,211495,DB00126,Vitamin C
,1315736,half-life,"When injected intravenously to the rat, SMAC circulated bound to albumin with a half-life of 130 min.",Synthesis of a cytochrome c derivative with prolonged in vivo half-life and determination of ascorbyl radicals in the circulation of the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315736/),min,130,211496,DB00126,Vitamin C
,1315736,half-life,We have synthesized an SM-conjugated superoxide dismutase (SOD) derivative (SM-SOD) that circulates bound to albumin with a half-life of 6 h.,Synthesis of a cytochrome c derivative with prolonged in vivo half-life and determination of ascorbyl radicals in the circulation of the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315736/),h,6,211497,DB00126,Vitamin C
,6831427,half-life,"The half-life of nitrate in the body was found to be approximately 5 hr, and its volume of distribution was about 30% of body weight.",Metabolic fate of an oral dose of 15N-labeled nitrate in humans: effect of diet supplementation with ascorbic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831427/),h,5,218852,DB00126,Vitamin C
,6831427,biosynthesis,Daily endogenous biosynthesis of nitrate was estimated to be about 1 mmol/day.,Metabolic fate of an oral dose of 15N-labeled nitrate in humans: effect of diet supplementation with ascorbic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831427/),mm,1,218853,DB00126,Vitamin C
,19041063,overall response rate (ORR,"Complete responses (CR) were seen in 12 of 48 patients (25%), with an overall response rate (ORR = CR + PR) of 85%.",Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041063/),%,85,221266,DB00126,Vitamin C
,19041063,progression-free survival (PFS),Median progression-free survival (PFS) was 25 months; median overall survival (OS) has not yet been reached.,Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041063/),month,25,221267,DB00126,Vitamin C
,8456071,disintegration time,Four formulations of 500-mg vitamin C tablets ranging in mean disintegration time from 9 to 120 min were compared with a standard vitamin C solution in a double-blind clinical trial with 15 subjects.,Correlation between the disintegration time and the bioavailability of vitamin C tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8456071/),min,9 to 120,223642,DB00126,Vitamin C
,33388522,flow rate,Separation of the analyte was achieved using ACQUITY UPLC BEH C18 column (1.7 µm) and mobile phase as water containing 0.1% Acetonitrile (40: 60% v/v) at a flow rate of 0.4 mL·min-1.,Development and validation of a new UPLC-MS/MS method for quantification of ganoderic acid-A loaded nanolipidic carrier in rat plasma and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388522/),[ml] / [min],0.4,223737,DB00126,Vitamin C
,11177201,incorporation,Geometric mean 58Fe incorporation was 7.6% (range 3.3-13.5%) with Protocol A as compared to 10.6% (range 6.7-18.6%) with Protocol B (P = 0.05); paired t test.,"Erythrocyte incorporation of iron by infants: iron bioavailability from a low-iron infant formula and an evaluation of the usefulness of correcting erythrocyte incorporation values, using a reference dose or plasma ferritin concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177201/),%,7.6,229512,DB00126,Vitamin C
,11177201,incorporation,Geometric mean 58Fe incorporation was 7.6% (range 3.3-13.5%) with Protocol A as compared to 10.6% (range 6.7-18.6%) with Protocol B (P = 0.05); paired t test.,"Erythrocyte incorporation of iron by infants: iron bioavailability from a low-iron infant formula and an evaluation of the usefulness of correcting erythrocyte incorporation values, using a reference dose or plasma ferritin concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177201/),%,10.6,229513,DB00126,Vitamin C
,11738270,VC,"The means (SD) of VC and TAS in healthy subjects were 2.22 (0.16) mmol/l and 0.48 (0.10) mg/dl, respectively.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mM] / [l],2.22,230315,DB00126,Vitamin C
,11738270,TAS,"The means (SD) of VC and TAS in healthy subjects were 2.22 (0.16) mmol/l and 0.48 (0.10) mg/dl, respectively.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mg] / [dl],0.48,230316,DB00126,Vitamin C
,11738270,distribution volume,"The pharmacokinetic results in vivo were as follows: means (SD) of distribution volume, area under curve, plasma clearance, half life, C(max), and T(max) were 32.0 (4.4) l, 36.4 (11.3) mg h/dl, 2.13 (1.36) l/h, 10.2 (7.8) h, 17.1 (7.1) mg/dl, and 0.64 (0.24) h, respectively.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),l,32.0,230317,DB00126,Vitamin C
,11738270,T(max),"The pharmacokinetic results in vivo were as follows: means (SD) of distribution volume, area under curve, plasma clearance, half life, C(max), and T(max) were 32.0 (4.4) l, 36.4 (11.3) mg h/dl, 2.13 (1.36) l/h, 10.2 (7.8) h, 17.1 (7.1) mg/dl, and 0.64 (0.24) h, respectively.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),h,0.64,230318,DB00126,Vitamin C
,11738270,TAS,"The means of TAS were increased over 5 consecutive days as 2.26, 2.76, 2.81, 3.18, and 3.58 mmol/l in paraquat patients.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mM] / [l],2.26,230319,DB00126,Vitamin C
,11738270,TAS,"The means of TAS were increased over 5 consecutive days as 2.26, 2.76, 2.81, 3.18, and 3.58 mmol/l in paraquat patients.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mM] / [l],2.76,230320,DB00126,Vitamin C
,11738270,TAS,"The means of TAS were increased over 5 consecutive days as 2.26, 2.76, 2.81, 3.18, and 3.58 mmol/l in paraquat patients.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mM] / [l],2.81,230321,DB00126,Vitamin C
,11738270,TAS,"The means of TAS were increased over 5 consecutive days as 2.26, 2.76, 2.81, 3.18, and 3.58 mmol/l in paraquat patients.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mM] / [l],3.18,230322,DB00126,Vitamin C
,11738270,TAS,"The means of TAS were increased over 5 consecutive days as 2.26, 2.76, 2.81, 3.18, and 3.58 mmol/l in paraquat patients.",Effect of vitamin C on plasma total antioxidant status in patients with paraquat intoxication. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11738270/),[mM] / [l],3.58,230323,DB00126,Vitamin C
,14564940,Relative bioavailability,"Relative bioavailability was lower (p < .05) than 100% for iron (80%), zinc (70%), and folate (85%).","Bioavailability of iron, zinc, folate, and vitamin C in the IRIS multi-micronutrient supplement: effect of combination with a milk-based cornstarch porridge. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564940/),%,100,240261,DB00126,Vitamin C
,14564940,Relative bioavailability,"Relative bioavailability was lower (p < .05) than 100% for iron (80%), zinc (70%), and folate (85%).","Bioavailability of iron, zinc, folate, and vitamin C in the IRIS multi-micronutrient supplement: effect of combination with a milk-based cornstarch porridge. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564940/),%,80,240262,DB00126,Vitamin C
,14564940,Relative bioavailability,"Relative bioavailability was lower (p < .05) than 100% for iron (80%), zinc (70%), and folate (85%).","Bioavailability of iron, zinc, folate, and vitamin C in the IRIS multi-micronutrient supplement: effect of combination with a milk-based cornstarch porridge. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564940/),%,70,240263,DB00126,Vitamin C
,14564940,Relative bioavailability,"Relative bioavailability was lower (p < .05) than 100% for iron (80%), zinc (70%), and folate (85%).","Bioavailability of iron, zinc, folate, and vitamin C in the IRIS multi-micronutrient supplement: effect of combination with a milk-based cornstarch porridge. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564940/),%,85,240264,DB00126,Vitamin C
,19874953,body pool,"The average body pool of vitamin C is 1.5 g, of which 3%-4% (40-60 mg) is used daily.",Vitamin C requirements in parenteral nutrition. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874953/),g,1.5,240332,DB00126,Vitamin C
,8369010,relative bioavailability,"After administration of 2 dragées of the test medication and determination of serum iron level until 9 h p.a., a relative bioavailability of 64%, compared to an equal dose of a ferrous-II-sulfate-ascorbic acid reference solution, was calculated.",[Pharmacokinetics and relative bioavailability of iron and folic acid in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369010/),%,64,243038,DB00126,Vitamin C
,8369010,relative bioavailability,From the serum folate AUC (0-9 h) the relative bioavailability was evaluated with 97% for the oral formulation compared to the i.m. administration.,[Pharmacokinetics and relative bioavailability of iron and folic acid in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369010/),%,97,243039,DB00126,Vitamin C
,29522710,trough concentrations,"With 2 g/d bolus, plasma vitamin C concentrations at 1 h were 29 to 50 mg/L and trough concentrations were 5.6 to 16 mg/L.",Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522710/),[mg] / [l],5.6 to 16,245850,DB00126,Vitamin C
,29522710,steady-state concentrations,"With 2 g/d continuous, steady-state concentrations were 7 to 37 mg/L at 48 h.",Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522710/),[mg] / [l],7 to 37,245851,DB00126,Vitamin C
,29522710,1-h,"With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L.",Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522710/),[mg] / [l],186 to 244,245852,DB00126,Vitamin C
,29522710,concentrations,"With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L.",Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522710/),[mg] / [l],186 to 244,245853,DB00126,Vitamin C
,29522710,trough concentrations,"With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L.",Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522710/),[mg] / [l],14 to 55,245854,DB00126,Vitamin C
,29522710,steady-state concentrations,"With 10 g/d continuous, steady-state concentrations were 40 to 295 mg/L at 48 h.",Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522710/),[mg] / [l],40 to 295,245855,DB00126,Vitamin C
,30884884,elimination rate constant,"Both substances decayed in more than bi-exponential pattern, with an elimination rate constant of 1.2 h-1 for IQ and 1.7 h-1 for epi-IQ.",Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30884884/),1/[h],1.2,247058,DB00126,Vitamin C
,30884884,elimination rate constant,"Both substances decayed in more than bi-exponential pattern, with an elimination rate constant of 1.2 h-1 for IQ and 1.7 h-1 for epi-IQ.",Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30884884/),1/[h],1.7,247059,DB00126,Vitamin C
,30884884,oral absolute bioavailability,"The oral absolute bioavailability for IQ was 38%, and, that for epi-IQ, was 13%.",Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30884884/),%,38,247060,DB00126,Vitamin C
,30884884,oral absolute bioavailability,"The oral absolute bioavailability for IQ was 38%, and, that for epi-IQ, was 13%.",Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30884884/),%,13,247061,DB00126,Vitamin C
,17065354,half-life,"The half-life of plasma glucosamine after oral dosing was approximately 150 min, with no significant changes in steady-state glucosamine levels detectable after 6 weeks of therapy.",Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17065354/),min,150,249096,DB00126,Vitamin C
,7064899,metabolic clearance,The average metabolic clearance was approximately 77 (ml hr-1) kg-1 and the average half-life was approximately 4.6 h for all caffeine administrations.,The effect of vitamin C on the pharmacokinetics of caffeine in elderly men. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7064899/),[ml] / [hr·kg],77,252069,DB00126,Vitamin C
,7064899,half-life,The average metabolic clearance was approximately 77 (ml hr-1) kg-1 and the average half-life was approximately 4.6 h for all caffeine administrations.,The effect of vitamin C on the pharmacokinetics of caffeine in elderly men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7064899/),h,4.6,252070,DB00126,Vitamin C
,8809386,rate of elimination,After i.v. administration the rate of elimination was greater at the high dose than the low (0.8560 vs 0.5231 h-1) but the area under the curve (AUC) parameter was proportional to the dosage (127.9 vs 39.7 mcg*h/mL).,Pharmacokinetic study of ascorbic acid in sheep. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809386/),1/[h],0.8560,256684,DB00126,Vitamin C
,8809386,rate of elimination,After i.v. administration the rate of elimination was greater at the high dose than the low (0.8560 vs 0.5231 h-1) but the area under the curve (AUC) parameter was proportional to the dosage (127.9 vs 39.7 mcg*h/mL).,Pharmacokinetic study of ascorbic acid in sheep. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809386/),1/[h],0.5231,256685,DB00126,Vitamin C
,8809386,area under the curve (AUC),After i.v. administration the rate of elimination was greater at the high dose than the low (0.8560 vs 0.5231 h-1) but the area under the curve (AUC) parameter was proportional to the dosage (127.9 vs 39.7 mcg*h/mL).,Pharmacokinetic study of ascorbic acid in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809386/),[h·mcg] / [ml],127.9,256686,DB00126,Vitamin C
,8809386,area under the curve (AUC),After i.v. administration the rate of elimination was greater at the high dose than the low (0.8560 vs 0.5231 h-1) but the area under the curve (AUC) parameter was proportional to the dosage (127.9 vs 39.7 mcg*h/mL).,Pharmacokinetic study of ascorbic acid in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809386/),[h·mcg] / [ml],39.7,256687,DB00126,Vitamin C
,8344797,half-life,"Exogenous H2O2 in aqueous humor decays with a half-life of 20 minutes, chiefly as a result of catalase activity.",Does topical hydrogen peroxide penetrate the cornea? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8344797/),min,20,258025,DB00126,Vitamin C
,25214322,Cmax,"Swiss Outbred mice were orally administered 0.76mg/kg EGCg, and using a validated HPLC method, the Cmax of un-conjugated and total EGCg was determined to be 31.5±3.3 and 34.3±2.0nM, respectively (mean±s.d., n=3-5).",Assessment of plasma concentrations of (-)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25214322/),nM,31.5,258518,DB00126,Vitamin C
,25214322,Cmax,"Swiss Outbred mice were orally administered 0.76mg/kg EGCg, and using a validated HPLC method, the Cmax of un-conjugated and total EGCg was determined to be 31.5±3.3 and 34.3±2.0nM, respectively (mean±s.d., n=3-5).",Assessment of plasma concentrations of (-)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25214322/),nM,34.3,258519,DB00126,Vitamin C
,25214322,area under the plasma concentration versus time curve,"The area under the plasma concentration versus time curve for un-conjugated and total EGCg was 114.3±4.1 and 116.4±4.1nM·h, respectively (mean±s.d., n=3-5).",Assessment of plasma concentrations of (-)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25214322/),h·nM,114.3,258520,DB00126,Vitamin C
,25214322,area under the plasma concentration versus time curve,"The area under the plasma concentration versus time curve for un-conjugated and total EGCg was 114.3±4.1 and 116.4±4.1nM·h, respectively (mean±s.d., n=3-5).",Assessment of plasma concentrations of (-)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25214322/),h·nM,116.4,258521,DB00126,Vitamin C
,844951,half-life,"In whole blood, mean concentrations of ascorbate declined with a half-life of about 34 h.",Blood levels and bioavailability of ascorbic acid after administration of a sustained-release formulation to humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/844951/),h,34,261552,DB00126,Vitamin C
,844951,bioavailability,The bioavailability of ascorbate from the sustained-release formulation was 149% and 180% of that from the standard formulation by calculation from whole blood and plasma concentration data respectively.,Blood levels and bioavailability of ascorbic acid after administration of a sustained-release formulation to humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/844951/),%,149,261553,DB00126,Vitamin C
,844951,bioavailability,The bioavailability of ascorbate from the sustained-release formulation was 149% and 180% of that from the standard formulation by calculation from whole blood and plasma concentration data respectively.,Blood levels and bioavailability of ascorbic acid after administration of a sustained-release formulation to humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/844951/),%,180,261554,DB00126,Vitamin C
,18535406,half-life,(188)Re-6D2 was quickly cleared from the blood with the half-life of approximately 5 hrs and from the body--with the half-life of 10 hr.,Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18535406/),h,5,262588,DB00126,Vitamin C
,18535406,half-life,(188)Re-6D2 was quickly cleared from the blood with the half-life of approximately 5 hrs and from the body--with the half-life of 10 hr.,Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18535406/),h,10,262589,DB00126,Vitamin C
,16153662,F,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),%,138,264249,DB00126,Vitamin C
,16153662,F,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),%,100,264250,DB00126,Vitamin C
,16153662,urinary excretion,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),%,5.18,264251,DB00126,Vitamin C
,16153662,urinary excretion,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),%,1.32,264252,DB00126,Vitamin C
,16153662,urine output,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),ml,41.3,264253,DB00126,Vitamin C
,16153662,urine output,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),ml,23.0,264254,DB00126,Vitamin C
,16153662,urinary excretion of sodium,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),[mM] / [kg],24.6,264255,DB00126,Vitamin C
,16153662,urinary excretion of sodium,"After oral administration of azosemide (20 mg/kg) with 100 mg of ascorbic acid, the F value (138% vs. 100%), 8-h urinary excretion of azosemide (5.18% vs. 1.32% of oral dose), 8-h urine output (41.3 vs. 23.0 ml), and 8-h urinary excretion of sodium (24.6 vs. 15.3 mmol/kg) were greater than controls (without ascorbic acid).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),[mM] / [kg],15.3,264256,DB00126,Vitamin C
,16153662,urine output,"After oral administration of azosemide with NH4Cl, the urine pH decreased by 0.5 U, and 8-h urine output (25.8 vs. 11.0 ml) and 8-h urinary excretion of sodium (13.3 vs. 6.89 mmol/kg) were significantly greater than controls (without NH4Cl).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),ml,25.8,264257,DB00126,Vitamin C
,16153662,urine output,"After oral administration of azosemide with NH4Cl, the urine pH decreased by 0.5 U, and 8-h urine output (25.8 vs. 11.0 ml) and 8-h urinary excretion of sodium (13.3 vs. 6.89 mmol/kg) were significantly greater than controls (without NH4Cl).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),ml,11.0,264258,DB00126,Vitamin C
,16153662,urinary excretion of sodium,"After oral administration of azosemide with NH4Cl, the urine pH decreased by 0.5 U, and 8-h urine output (25.8 vs. 11.0 ml) and 8-h urinary excretion of sodium (13.3 vs. 6.89 mmol/kg) were significantly greater than controls (without NH4Cl).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),[mM] / [kg],13.3,264259,DB00126,Vitamin C
,16153662,urinary excretion of sodium,"After oral administration of azosemide with NH4Cl, the urine pH decreased by 0.5 U, and 8-h urine output (25.8 vs. 11.0 ml) and 8-h urinary excretion of sodium (13.3 vs. 6.89 mmol/kg) were significantly greater than controls (without NH4Cl).",Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153662/),[mM] / [kg],6.89,264260,DB00126,Vitamin C
,2287031,percentage bioavailability,"For intramuscular injection two preparations were studied, and the percentage bioavailability up to 24 h of 10 g of ascorbic acid was 95% +/- 22 in four horses and 60% in two horses with preparations A and B, respectively.",Bioavailability of ascorbic acid in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287031/),%,95,269907,DB00126,Vitamin C
,2287031,percentage bioavailability,"For intramuscular injection two preparations were studied, and the percentage bioavailability up to 24 h of 10 g of ascorbic acid was 95% +/- 22 in four horses and 60% in two horses with preparations A and B, respectively.",Bioavailability of ascorbic acid in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287031/),%,60,269908,DB00126,Vitamin C
,2287031,Bioavailability,Bioavailability at 24 h in three horses injected subcutaneously with 10 g of preparation B was 82%.,Bioavailability of ascorbic acid in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287031/),%,82,269909,DB00126,Vitamin C
,10406209,limit of detection,The limit of detection for etoposide was 1.2 nM and for etoposide catechol was 0.2 nM.,Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),nM,1.2,270932,DB00126,Vitamin C
,10406209,limit of detection,The limit of detection for etoposide was 1.2 nM and for etoposide catechol was 0.2 nM.,Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),nM,0.2,270933,DB00126,Vitamin C
,10406209,Recovery,"Recovery of etoposide and etoposide catechol ranged from 93 to 95% and 90 to 98%, respectively.",Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),%,93 to 95,270934,DB00126,Vitamin C
,10406209,Recovery,"Recovery of etoposide and etoposide catechol ranged from 93 to 95% and 90 to 98%, respectively.",Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),%,90 to 98,270935,DB00126,Vitamin C
,25129410,extraction recovery,"Some pretreatment variables (protein precipitating solvent, acidifying agent and sorbent) were optimized with acceptable matrix effect (-18 to 7.7%), extraction recovery (65-88%) and process efficiency (62-91%) for the SMIPE-based LC-MRM multi-analyte quantitation using matrix-matched calibration (5-1000 ng/mL) without using internal standard.",Simultaneous multi-component quantitation of Chinese herbal injection Yin-zhi-huang in rat plasma by using a single-tube extraction procedure for mass spectrometry-based pharmacokinetic measurement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25129410/),%,65-88,272560,DB00126,Vitamin C
,25129410,process efficiency,"Some pretreatment variables (protein precipitating solvent, acidifying agent and sorbent) were optimized with acceptable matrix effect (-18 to 7.7%), extraction recovery (65-88%) and process efficiency (62-91%) for the SMIPE-based LC-MRM multi-analyte quantitation using matrix-matched calibration (5-1000 ng/mL) without using internal standard.",Simultaneous multi-component quantitation of Chinese herbal injection Yin-zhi-huang in rat plasma by using a single-tube extraction procedure for mass spectrometry-based pharmacokinetic measurement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25129410/),%,62-91,272561,DB00126,Vitamin C
,14555815,effective concentrations,"Further pharmacokinetic study into the systemic administration of these antioxidants is necessary, using effective concentrations of 5-40 mM for both N-acetyl-L-cysteine and glutathione, and 1-50 units of catalase.",Effects of N-acetyl-L-cysteine and glutathione on antioxidant status of human serum and 3T3 fibroblasts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555815/),m,5-40,273151,DB00126,Vitamin C
